Protagonist Therapeutics PTGX
United StatesHealthcare · BiotechnologyUSD
174.69 USD (+24.0%)
13 analysts
Trading 2120.30 €Open account ↗
Lightyear0.90 €Open account ↗
N260.90 €Open account ↗
XTB1.00 €★ featured · affiliateOpen account ↗Trading 2120.30 €Open account ↗Lightyear0.90 €Open account ↗XTB1.00 €★ featured · affiliateOpen account ↗200.00 € order · cheapest cheapest available in your country iCompare all 22 brokers →What does it do?
Protagonist Therapeutics is a commercial-stage biopharmaceutical company that develops and sells peptide therapies for inflammatory and immunological diseases, with a model based on proprietary research and strategic partnerships.
Key points
from its scores- ✓Strong growth10.0
- ✓Very solid balance sheet9.4
- ✓Good share-price trend9.3
- ✕Demanding valuation1.3
- ✕Little or no dividend1.5
AI analysis
bottom line, main risk, context and newsFundamentals are solid and growth is real, but the valuation leaves little room for error.
Protagonist Therapeutics shows exceptional financial health (net cash, DN/EBITDA -12.91) and explosive revenue growth (+3749%), with operating margins of 74.37% and an ROIC of 24.64%, although its valuation is extremely demanding (PER 136.82) and it pays no dividend.
The main risk is the extreme valuation (PER 136.82, EV/EBITDA 139.36): any disappointment in the growth trajectory or in the results of its pipeline drugs could trigger a severe correction.
Context and risks
No relevant recent news and no material exposure to current macro factors (rates, oil, shipping routes). The commercial-stage biotech business does not depend on commodities or significant external financing, with very high net cash.
Is Protagonist Therapeutics stock cheap or expensive?
at the analysis dateOn P/E and EV / EBITDA, it trades 637% above the Healthcare median on average.
| Multiple | Company | Sector | Difference |
|---|---|---|---|
| P/E | 136.8 | 26.7 | +412% |
| EV / EBITDA | 139.4 | 14.5 | +863% |
| Price / book | 10.8 | 4.1 | +164% |
| Price / sales | 32.3 | 3.4 | +846% |
Sector: median of the 217 Healthcare companies analysed. In bold, the multiples used for the comparison.
Valuation score: 1.3 out of 10 (median for Healthcare: 4.7).
Average analyst target: 174.69 USD, +24.0% versus the price.
A premium can be justified if the company is of higher quality or grows faster than its sector: Quality / Moat 8.3 (sector 5.5), Growth 10.0 (sector 6.6).
Classic formulas with standard assumptions (5.0% growth, 8-9% discount rate). Indicative only: they change a lot with the assumptions and are not a recommendation.
Work out its fair value yourself →How much would you have made investing every month? →
Comparing it with its sector does not say whether it is a good buy: this is not investment advice.
Score by category
0 to 10 · hover overtap each one to see what it measuresKey metrics
at the analysis date · compared with the Healthcare medianValuation
- P/E
- 136.8
- Forward P/E
- −707.6
- EV / EBITDA
- 139.4
- Price / book
- 10.8
- Price / sales
- 32.3
- Market cap
- 9.1B USD
- Enterprise value
- 8.3B USD
Profitability
- ROE
- 11.0%
- ROA
- 4.5%
- ROIC (approx.)
- 24.6%
- Gross margin
- 100.0%
- Operating margin
- 74.4%
- Net margin
- 29.4%
- Free cash flow
- 96.1M USD
- FCF yield
- 1.1%
- Cash conversion
- 161%
Solvency
- Total debt
- 9.2M USD
- Net debt
- −773.4M USD
- Cash
- 782.6M USD
- EBITDA
- 59.9M USD
- Net debt / EBITDA
- −12.91
- Debt / equity
- 1.09
- Current ratio
- 21.71
- Quick ratio
- 21.58
Growth
- Revenue growth
- +3,749.2%
- EPS (TTM)
- 1.03 USD
- EPS (forward)
- −0.20 USD
Dividend
- Dividend yield
- 0.0%
- Payout
- 0.0%
Risk and market
- Beta
- 1.52
- Analyst consensus
- Strong buy (13)
- Target price
- 174.69 USD
- 52-week range
- 64.50 – 160.81
Recent news
All PTGX news →Compare it with its sector
All 217 in Healthcare →Frequently asked questions about Protagonist Therapeutics
Is Protagonist Therapeutics stock cheap or expensive?
On P/E and EV / EBITDA, it trades 637% above the Healthcare median on average. Valuation score: 1.3 out of 10 (median for Healthcare: 4.7). Average analyst target: 174.69 USD, +24.0% versus the price. This is not investment advice.
What score does Protagonist Therapeutics get on MeridIAn Screener?
It scores 6.2 out of 10, rank 833 of 2,130 (better than 60% of the companies analysed). Its strongest category is Growth (10.0) and its weakest, Valuation (1.3). Analysis of 08/10/2026.
What is Protagonist Therapeutics's P/E ratio?
Its P/E is 136.8: the share price equals 136.8 times earnings per share over the last 12 months. The Healthcare median is 26.7.
How much is Protagonist Therapeutics worth on the stock market?
Its market capitalisation is 9.1B USD and its enterprise value, debt included, is 8.3B USD.
How much debt does Protagonist Therapeutics have?
It has more cash than debt: net cash of 773.4M USD.
Does Protagonist Therapeutics pay a dividend?
It pays no dividend, or almost none.
How has Protagonist Therapeutics stock performed over the last year?
It has risen 62.0% over the last year, excluding dividends. Over the last 52 weeks it has traded between 64.50 and 160.81 USD. Past performance does not guarantee future results.
What do analysts think of Protagonist Therapeutics?
13 analysts cover it; their average recommendation is “Strong buy” and their average target is 174.69 USD (+24.0% versus the price). It is an estimate, not market data.